Tibet Weixinkang Medicine Co., Ltd. (SHA:603676)

Market Cap	3.50B -29.1%
Revenue (ttm)	1.09B -6.7%
Net Income	190.23M -14.3%
EPS	0.44 -15.0%
Shares Out	432.33M
PE Ratio	18.39
Forward PE	n/a
Dividend	0.33 (4.04%)
Ex-Dividend Date	Jun 29, 2026

Volume	1,418,800
Open	8.22
Previous Close	8.24
Day's Range	8.06 - 8.27
52-Week Range	7.82 - 11.88
Beta	-0.02
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2026

About Tibet Weixinkang Medicine

Tibet Weixinkang Medicine Co., Ltd. engages in the research and development, production, and sale of chemical drugs and their bulk drugs in China. It offers APIs; multivitamins and pediatric multivitamins for injections; concentrate of trace elements solution for infusion; compound and pediatric compound amino acid injections; iron sucrose, multiple electrolytes, potassium aspartate and magnesium aspartate, carbohydrate and electrolyte, pentoxifylline, piracetam, and dopamine hydrochloride injections; and acetylcysteine solution for inhalation....

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 763
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603676

Financial Performance

In 2025, Tibet Weixinkang Medicine's revenue was 1.14 billion, a decrease of -12.65% compared to the previous year's 1.30 billion. Earnings were 232.85 million, a decrease of -5.41%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 13, 2026

Data Sources Report a data error